Aripiprazole Tablet
Product Images NDC 71335-0412

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71335-0412). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Fig1 Effectofotherdrug Arip

A figure titled 'The effects of other drugs on aripiprazole pharmacokinetics' showing a horizontal plot of aripiprazole fold change and 90% confidence intervals. It displays effects of various interacting drugs, including CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and others like valproate, lithium, and lorazepam, on aripiprazole area under the curve (AUC) and peak concentration (Cmax). The x-axis represents change relative to reference (without interacting drug) from 0.5 to 3.0.*

FDA Label Image

Image Fig2 Effectofotherdrug Dehydroarip

A horizontal bar chart titled 'The effects of other drugs on dehydro-aripiprazole pharmacokinetics.' It shows fold change and 90% confidence intervals of dehydro-aripiprazole AUC and Cmax when co-administered with various drug types including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam). The x-axis represents change relative to a reference without interacting drugs, ranging from 0.0 to 3.0.*

FDA Label Image

Image Fig3 Effectofarip Otherdrug

A figure titled 'The effects of aripiprazole on pharmacokinetics of other drugs' showing a forest plot of fold changes with 90% confidence intervals. It presents the effect of aripiprazole on various drugs including dextromethorphan, S- and R-warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The x-axis measures change relative to reference (without interacting drug) from 0.5 to 3.0.*

FDA Label Image

Image Fig4 Effectofintrinsicfactor Arip

A chart titled 'Effects of intrinsic factors on aripiprazole pharmacokinetics' showing fold changes and 90% confidence intervals in aripiprazole exposure for special populations. Categories include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with pharmacokinetic measures AUC and Cmax plotted against change relative to reference on the x-axis.*

FDA Label Image

Image Fig5 Effectofintrinsicfactor Dehydroarip

A pharmacokinetic chart titled 'Effects of intrinsic factors on dehydro-aripiprazole pharmacokinetics' showing fold change and 90% confidence intervals for different intrinsic factors. The x-axis represents change relative to reference, while the y-axis lists factors such as CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. Data points compare AUC and Cmax values for these categories.*

FDA Label Image

Image Fig6 Schizophreniastudy 5

A Kaplan-Meier curve chart depicting the cumulative proportion of patients with relapse over a 182-day period in a schizophrenia study comparing aripiprazole and placebo groups. The vertical axis shows the proportion with relapse, while the horizontal axis indicates days from randomization. The graph includes a table of the number of subjects at risk for both treatment groups at various time points.*

FDA Label Image

Image Fig7 Bipolarstudy 7

A Kaplan-Meier graph showing the cumulative proportion of patients with relapse over days from randomization in Bipolar Study 7. The graph compares aripiprazole (solid blue line) with placebo (dashed red line) with the y-axis representing the proportion with relapse and the x-axis showing days from randomization. The number of subjects at risk for both groups is listed below the x-axis.*

FDA Label Image

Image Fig8 Bipolarstudy 8

A Kaplan-Meier estimation graph showing the cumulative proportion of patients with relapse to any mood event over days from randomization. The graph compares two groups labeled as ABILIFY (solid blue line) and PLACEBO (dashed red line). The x-axis represents days from randomization (0 to 364), and the y-axis shows the proportion with relapse (0.0 to 1.0). A table below the x-axis lists the number of subjects at risk over time for each group.*

FDA Label Image

Image Fig9 Tourettesdisorderstudy1

A line graph titled 'Least Square Means of Change from Baseline in YGTSS TTS by Week (Tourette’s Disorder Study 1)' showing change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares three groups: ARIP LOW, ARIP HIGH, and PLACEBO, plotting their mean change scores on the y-axis against weeks of treatment on the x-axis.*

FDA Label Image

Image Logo Medguide

FDA Label Image

Image Logo Pi

FDA Label Image

Image Structure

Chemical structure of aripiprazole, showing its molecular arrangement including two chlorine atoms, several ring structures, and functional groups consistent with the compound's known chemical formula.*

FDA Label Image

Label Image (Lbl713350412)

Label for aripiprazole 20 mg tablet, an oral human prescription drug packaged by Bryant Ranch Prepack in Burbank, CA. The label compares the product to Abilify 20 mg tablet by Torrent Pharmaceuticals Ltd., and indicates a 30-count package. Storage instructions specify room temperature 20°-25°C (68°-77°F). NDC 71335-0412 is shown along with a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.